Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 109

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 109
---
Healthy China 2030". Healthcare is one of the growth priorities with policies aimed at addressing a large and increasing burden of disease (especially cancer, diabetes and cardiovascular diseases), while balancing access to innovation and costs. China also continues to improve regulatory timelines . For example, Dupixent received approval for the treatment of adults with moderate-to-severe AD in June 2020, within six months of filing through an accelerated review process. Pricing pressure is expected to remain at a high level as a growing number of products are subject to National Reimbursement Drug List (NRDL) price negotiations and volume-based procurement (VBP) tenders, with the lowest price prevailing to compete with local champions. Access to innovative therapies has been accelerating in the last five years, fueled by annual NRDL updates, albeit with steep price cuts across therapy areas. According to the National Healthcare Security Administration (NHSA), 91 new drugs were added to the National Reimbursement Drug List (NRDL) in December 2024, with an average price cut of 63%, the highest level since NRDL updates began in 2017. More than 70% of successful medicines were developed by Chinese companies, continuing the recent growth in domestic manufacturers’ share of new entries to the NRDL. Additionally, 38 of the 91 new entries to the NRDL are in Class 1 where China is the global first-launch market. Further expansion of the VBP policy will pursue aggressive price cutting of a growing number of products, including biologics, with more than 500 drugs targeted for inclusion in 2025. B.6. Patents, intellectual property and other rights Intellectual property rights are essential to our business because they protect our innovations and investments in research and development, manufacturing and marketing of our products. Intellectual property rights include patents, trademarks, copyrights, know‑how, trade secrets and regulatory-based protection.

| SANOFIFORM 20-F2024 | 45 |

| PART I                             |
| ITEM 4. Information on the Company |

Patent protection We own a broad portfolio of patents, patent applications and patent licenses worldwide. These patents are of various types and may cover: active ingredients; pharmaceutical formulations; product manufacturing processes; intermediate chemical compounds; therapeutic indications/methods of use; technology platforms; delivery systems; digital applications; and enabling technologies, such as assays. Patent protection is considered, in the aggregate, to be of material importance to the marketing and sales of our products. Patent protection for individual products typically extends for 20 years from the